


















p53 functions as a longevity assurance gene (by virtue 
of its strong tumor suppressor activity) and a regulator 
of aging. In several mouse models, persistent low-level 
activation of p53, either through deregulated expression 
of p53 itself or in response to constitutive stress like 
DNA damage/telomere erosion, leads to premature 
aging [1,2]. However, mice with normal basal p53 
levels that have been engineered to a show a heightened 
ability to mount a p53 response show a very strong 
resistance to tumourigenesis without evidence of 
premature aging [3]. Indeed, in several of these models 
a decreased level of aging related damage is observed, 
indicating that p53 may also help to promote longevity. 
The control of aging reflects numerous activities of p53, 
including the modulation of the IGFR pathway through 
interplay between full-length p53 and N-terminally 
truncated splice variants of p53 [4] and the ability of 
p53 to restrict stem cell function [5]. p53 is also a key 
regulator of senescence, a central stress response that 
plays an important role in tumour suppression, but may 
also help to promote cancer development by inducing 
an inflammatory response [6]. The ability to control 
senescence is consistent with p53’s function in 
restraining cancer development, but can the 
mechanisms through which p53 regulates senescence 
also contribute to the control of aging? 
 
Induction of senescence by p53 is associated with the 
regulation of p53-dependent genes that can participate 
in cell cycle arrest. While depletion of these 
components can impact senescence induction – 
supporting their role in mediating this response – the 
inhibition of cell cycle progression alone does not 
explain how this arrest can be turned into the definitive 
and permanent proliferation block  that  is  characteristic  
 
 

















of senescence. Furthermore, despite the clear 
documentation of p53’s ability to induce senescence, 
more recent evidence shows that p53 can also function 
to inhibit senescence while promoting cell cycle arrest 
[7]. So how can p53 both suppress and promote 
senescence? An important component of this may be 
the ability of p53 to control cell growth and metabolic 
stress  through different pathways, including the 
regulation of ROS levels and the activity of mTOR 
(Figure 1). The ability of p53 to promote ROS 
production has been shown to participate in the 
induction of apoptosis by p53 [8]. But ROS are also 
known to be critical for senescence [9] and the p53 
target genes that increase ROS may also play an 
important role in senescence induction. However, p53 
also promotes the expression of a number of 
antioxidant genes, accounting for p53’s ability to 
control oxidative stress in cells and mice [10]. So 
p53’s ability to decrease and increase oxidative stress 
likely contributes to its dual effect on senescence. 
Another factor that influences the outcome to p53 
activation is mTOR. While mTOR is normally 
associated with cell growth, activation of mTOR can 
contribute to and be essential for certain types of 
senescence [11,12], and the maintenance of mTOR 
signalling under conditions of cell cycle arrest leads to 
senescence in cultured cells [13]. p53 inhibits the 
mTOR pathway at several levels [14], contributing to 
the anti-senescence activity of p53 [15]. Furthermore, 
mTOR can be activated by ROS [16], so p53's 
antioxidant activities may reinforce the dampening of 
mTOR and senescence (Figure 1).  
 
One of the main responses to mTOR inhibition is the 
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several possible links between autophagy and 
senescence. Inhibition of autophagy results in the 
accumulation of protein aggregates, ER stress and 
mitochondrial dysfunction, each of which could promote 
senescence. However, other studies suggest that 
autophagy may be required for an efficient senescence 
response [17]. In either case, the ability of p53 to both 
enhance and inhibit autophagy [18] provides a further 
mechanism for the modulation of senescence.  
 
The activity of p53 is regulated through many 
mechanisms, but of particular interest with respect to 
the control of senescence and aging is a role for the 
histone deacetylase Sirt1, whose expression is strongly 
down regulated in senescent cells [19]. In contrast 
nutrient deprivation, which inhibits mTOR and can 
impede cellular senescence [13], has been shown to 
increase Sirt1 levels [20]. One way in which Sirt1 
functions is to deacetylate p53, modulating p53 activity 
and decreasing senesence [21]. Deactylation inhibits 
p53’s ability to transcriptionally  activate some,  but not 
































induction, ROS production [22,23], and presumably 
also senescence (Figure 1). The presence of a chronic 
DNA damage response (as may be seen in cancer cells), 
which is linked to the induction of senescence [24], can 
directly increase p53 acetylation by inducing the 
phosphorylation of the N-terminus of p53 and so 
promoting the interaction with the acetyl transferases 
CBP/p300. Mouse models have shown that expression 
of phosphorylation resistant p53 inhibits the induction 
of senescence [25], while cells harbouring p53 with 
acetyl-mimicking mutations of the last seven lysine 
residues have an accelerated entry into senescence and 
are very resistant to senescence bypass [26], although the 
cell cycle arrest response in these cells remains normal. 
Phosphorylation and acetylation of p53 is also seen to be 
important during Ras-induced or replicative senescence 
[27,28]. Under these circumstances, it would seem that 
deacetylation of p53 by Sirt1 impedes the induction of 
senescence, as well as apoptosis. Taken together there is 
good evidence that acetylation of p53 promotes sense-
cence and apoptosis, so inhibitors of the deacetylation 
enzymes might be useful drugs for the reactivation of 
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of senescence by p53 have also been linked to the 
regulation of longevity. Induction of mTOR and 
oxidative stress – and the complex interplay between 
them – is associated with aging [16] and Sirt1 is 
emerging as a key supporter of longevity in many 
organisms [30]. The induction of cellular senescence 
itself may result in loss of tissue renewal and 
architecture, organ dysfunction and organismal aging 
[31], while autophagy can protect from aging [32]. So it 
seems reasonable to propose that p53’s ability to 
influence aging is reflected – at least in part - by the 
mechanisms through which p53 controls senescence. 
But as we have discussed, p53 can promote and impede 
both senescence and aging - so which output prevails? 
The answer is not yet clear, but one determining factor 
may be the type or extent of the p53-inducing stress. 
Current models suggest that mild or constitutive stress 
induced by normal growth and proliferation lead to p53-
induced antioxidant and repair functions, while strong 
or persistent p53 activity may tip the balance towards 
the induction of apoptosis or senescence, thereby 
favoring aging. The mouse models also clearly suggest 
that inappropriate p53 activity promotes aging while a 
robust but normally regulated p53 response protects 
from the aging process. One prediction of this model is 
that the persistent stress encountered in tumors would 
favor p53-induced senescence over a more transient cell 
cycle arrest – and indeed the activation of p53 in 
established tumors has been shown to promote 
senescence in some tissue types [33].  
 
p53 is emerging as an important, but complex, player in 
the regulation of senescence and longevity. The ability 
of p53 to both activate and inhibit senescence is 
reflected in the ability to promote and inhibit oxidative 
stress and autophagy, and the ultimate establishment of 
senescence or quiescence is highly dependent on 
collaborating factors such as mTOR activity or 
oxidative stress. Ultimately, these bipolar activities of 
p53 become manifest in the contradictory effects on 
longevity and aging. p53 based cancer therapies may be 
rendered more effective by an increased propensity of 
transformed cells to undergo senescence, compared to 
normal cells. However, the idea that p53 can both 
promote and prevent aging adds even more spice to the 
consideration of how to use drugs that can induce or 
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